0Studies tracked
0Claims cite
0Videos use
Average study score: 6/100
Bibliography
Studies by this author
1 study attributed to Truman Hirkala-Schaefer on the platform. Click a card to read the full analysis.
Study
Abstract 1642: A pan-RASi antibody-drug conjugate platform with high activity in RAS-mutant cancers
To develop a novel pan-RAS inhibitor antibody-drug conjugate (ADC) platform aimed at improving anti-tumor efficacy and tolerability compared with orally administered pan-RAS inhibitors such as RMC-6236 for RAS-mutant cancers.